The global immunology market size was estimated to be USD 107.66 billion in 2023 and is expected to reach at USD 288.08 billion by 2034 with a CAGR of 9.36% during the forecast period 2024-2034. Increasing prevalence of immunological disorders, growing awareness about immunological diseases such as rheumatoid arthritis, psoriatic arthritis, & type I diabetes, surge in adoption of immunology drugs, increasing demand for biosimilars, and rising regulatory approvals of novel drugs are some of the key factors boosting the market growth.
Rising regulatory approvals of novel drugs is predicted to boost the market growth during the forecast period. The current market participants concentrate on enhancing and developing their goods on a continuous basis for better patient care and patient outcomes. For instance, in June 2022, Eli Lilly and Company has obtained FDA approval in the United States for OLUMIANT as the initial systemic treatment for severe alopecia areata (AA), an autoimmune condition, in adults.
By drug class, monoclonal antibody (mAb) was the highest revenue-grossing segment in the global immunology market in 2023 owing to increasing prevalence of autoimmune diseases and rising product approvals by regulatory bodies. For instance, in March 2022, AbbVie Inc. has obtained approval from the U.S. FDA for Rinvoq as a treatment for moderate to severely active ulcerative colitis in adult patients. Additionally, immunosuppressants is predicted to grow at fastest CAGR during the forecast period owing to the growing focus on research & development activities, increasing approvals by regulatory bodies for novel drugs, rising adoption of immunosuppressants.
By indication, rheumatoid arthritis was the highest revenue-grossing segment in the global immunology market in 2023 owing to rising prevalence of rheumatoid arthritis, surge in number of patients undergoing treatment, and increasing launch of advanced therapies. Additionally, ankylosing spondylitis is predicted to grow at fastest CAGR during the forecast period owing to the growing research & development activities, increasing demand for advanced treatments, and rising approvals by regulatory bodies. For instance, in April 2022, AbbVie Inc has revealed that the U.S. Food and Drug Administration (FDA) granted approval to RINVOQ for treating active ankylosing spondylitis (AS) in adult patients.
By distribution channel, hospital pharmacies was the highest revenue-grossing segment in the global immunology market in 2023 owing to the surge in individuals with autoimmune or immunological illnesses & the number of hospitalizations & doctor visits, increase in well-established healthcare infrastructure, and rising marketing approvals by regulatory authorities. For instance, in February 2022, Health Canada has granted marketing authorization to UCB S.A. for BIMZELX (bimekizumab injection), allowing its use in treating adults with moderate to severe plaque psoriasis who are eligible for systemic therapy or phototherapy. Additionally, online pharmacies is predicted to grow at fastest CAGR during the forecast period owing to the Changing regulations for prescription medicine sales online, along with the advent of major e-pharmacy operators, rising customer preference towards online pharmacies.
North America region is anticipated for the highest revenue share during the forecast period owing to the surge in prevalence of chronic disorders, increase in advanced healthcare infrastructure, growing demand for advanced diagnosis, and rising mergers & acquisitions within market players. For instance, in March 2022, Pfizer Inc. has finalized its purchase of Arena Pharmaceuticals, a clinical-stage enterprise working on promising treatments for various immuno-inflammatory ailments. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising prevalence of autoimmune disorders, growing demand for preventive care, increasing launch of new drugs, and surge in approvals of innovative drugs. For instance, in January 2022, UCB S.A. has obtained approval from the Japanese Ministry of Health, Labor, and Welfare to market BIMZELX for the treatment of plaque psoriasis.
Rising regulatory approvals of novel drugs is predicted to boost the market growth during the forecast period. The current market participants concentrate on enhancing and developing their goods on a continuous basis for better patient care and patient outcomes. For instance, in June 2022, Eli Lilly and Company has obtained FDA approval in the United States for OLUMIANT as the initial systemic treatment for severe alopecia areata (AA), an autoimmune condition, in adults.
By drug class, monoclonal antibody (mAb) was the highest revenue-grossing segment in the global immunology market in 2023 owing to increasing prevalence of autoimmune diseases and rising product approvals by regulatory bodies. For instance, in March 2022, AbbVie Inc. has obtained approval from the U.S. FDA for Rinvoq as a treatment for moderate to severely active ulcerative colitis in adult patients. Additionally, immunosuppressants is predicted to grow at fastest CAGR during the forecast period owing to the growing focus on research & development activities, increasing approvals by regulatory bodies for novel drugs, rising adoption of immunosuppressants.
By indication, rheumatoid arthritis was the highest revenue-grossing segment in the global immunology market in 2023 owing to rising prevalence of rheumatoid arthritis, surge in number of patients undergoing treatment, and increasing launch of advanced therapies. Additionally, ankylosing spondylitis is predicted to grow at fastest CAGR during the forecast period owing to the growing research & development activities, increasing demand for advanced treatments, and rising approvals by regulatory bodies. For instance, in April 2022, AbbVie Inc has revealed that the U.S. Food and Drug Administration (FDA) granted approval to RINVOQ for treating active ankylosing spondylitis (AS) in adult patients.
By distribution channel, hospital pharmacies was the highest revenue-grossing segment in the global immunology market in 2023 owing to the surge in individuals with autoimmune or immunological illnesses & the number of hospitalizations & doctor visits, increase in well-established healthcare infrastructure, and rising marketing approvals by regulatory authorities. For instance, in February 2022, Health Canada has granted marketing authorization to UCB S.A. for BIMZELX (bimekizumab injection), allowing its use in treating adults with moderate to severe plaque psoriasis who are eligible for systemic therapy or phototherapy. Additionally, online pharmacies is predicted to grow at fastest CAGR during the forecast period owing to the Changing regulations for prescription medicine sales online, along with the advent of major e-pharmacy operators, rising customer preference towards online pharmacies.
North America region is anticipated for the highest revenue share during the forecast period owing to the surge in prevalence of chronic disorders, increase in advanced healthcare infrastructure, growing demand for advanced diagnosis, and rising mergers & acquisitions within market players. For instance, in March 2022, Pfizer Inc. has finalized its purchase of Arena Pharmaceuticals, a clinical-stage enterprise working on promising treatments for various immuno-inflammatory ailments. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising prevalence of autoimmune disorders, growing demand for preventive care, increasing launch of new drugs, and surge in approvals of innovative drugs. For instance, in January 2022, UCB S.A. has obtained approval from the Japanese Ministry of Health, Labor, and Welfare to market BIMZELX for the treatment of plaque psoriasis.
Segmentation: Immunology Market Report 2022 - 2033
Immunology Market Analysis & Forecast by Drug Class 2023 - 2034 (Revenue USD Bn)
- Fusion Proteins
- Immunosuppressants
- Monoclonal Antibody (mAb)
- Others
Immunology Market Analysis & Forecast by Indication 2023 - 2034 (Revenue USD Bn)
- Ankylosing Spondylitis
- Psoriatic Arthritis
- Plaque Psoriasis
- Rheumatoid Arthritis
- Inflammatory Bowel Diseases
- Prophylaxis of Organ Rejection
- Others
Immunology Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Online Pharmacies
- Hospital Pharmacies
- Retail Pharmacies
Immunology Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Immunology Market: Drug Class Estimates & Trend Analysis
8. Immunology Market: Indication Estimates & Trend Analysis
9. Immunology Market: Distribution Channel Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Immunology Market
12. Europe Global Immunology Market
13. Asia Pacific Global Immunology Market
14. Latin America Global Immunology Market
15. MEA Global Immunology Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Eli Lilly and Company
- AstraZeneca
- AbbVie
- UCB S.A.
- Janssen Global Services LLC
- Novartis AG
- Astellas Pharma Inc
- F. Hoffman-La Roche
- Amgen Inc
- Merck Sharp & Dohme Corp.
- Pfizer Inc
- Bristol-Myers Squibb Company
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | October 2023 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 107.66 Billion |
| Forecasted Market Value ( USD | $ 288.08 Billion |
| Compound Annual Growth Rate | 9.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 12 |
